Actively Recruiting
Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
Led by Claus Cursiefen · Updated on 2024-10-21
110
Participants Needed
7
Research Sites
253 weeks
Total Duration
On this page
Sponsors
C
Claus Cursiefen
Lead Sponsor
U
Uniklinik Köln, Zentrum für Klinische Studien
Collaborating Sponsor
AI-Summary
What this Trial Is About
The trial evaluates the effect of corneal crosslinking as pre-treatment before corneal transplantation. The goal is to improve graft survival by reducing pathological vessels through pre-treatment.
CONDITIONS
Official Title
Pretreatment to Promote Graft Survival After Subsequent High-risk Corneal Transplantation [CrossCornealVision]
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Pathologically prevascularized cornea with need for corneal transplantation
- Written informed consent given before any study procedures
- Adults aged 18 years or older
- At least 2 corneal quadrants covered by pathological corneal neovascularization
- No clinical contraindications to any part of the treatment plan
- Willingness to cooperate and follow study procedures
- Only one eye included if both eyes affected
- Steroid responders can participate if controlled by therapy
You will not qualify if you...
- Less than 2 corneal quadrants covered by pathological neovascularization
- Corneal stromal thickness below 400 bcm except in central 8 mm zone
- Active or suspected intraocular inflammation
- Active corneal ulceration
- Compromised eyelid mobility or symblepharon
- Allergy or intolerance to riboflavin or UV light
- Contraindications to antibiotics, corticosteroids, or surgical protocol
- Clinically significant or unstable diseases affecting grafting
- Rheumatic diseases on systemic immunosuppressants
- Unable to comply with study protocol or understand study procedures
- Participation in another investigational drug trial within 4 weeks
- HIV positive
- Known abuse of alcohol, drugs, or medicines
- Any medical or psychiatric condition affecting compliance or safety
- Employees or relatives of sponsor or investigator
- Pregnant or nursing women
- Persons legally institutionalized
- Dysregulated glaucoma with intraocular pressure > 25 mmHg despite therapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Augenklinik des Klinikums der Universität München
München, Bavaria, Germany, 80336
Actively Recruiting
2
University Hospital of Cologne, Centre for Ophthalmology
Cologne, North Rhine-Westphalia, Germany, 50937
Actively Recruiting
3
Universitätsklinikum Düsseldorf, Klinik für Augenheilkunde
Düsseldorf, North Rhine-Westphalia, Germany, 40225
Actively Recruiting
4
Universitätsklinikum des Saarlandes, Klinik für Augenheilkunde
Homburg, Saarland, Germany, 66424
Actively Recruiting
5
Charité - Universitätsmedizin Berlin, Klinik für Augenheilkunde
Berlin, Germany, 13353
Actively Recruiting
6
Universitätsklinikum Freiburg, Klinik für Augenheilkunde
Freiburg im Breisgau, Germany, 79106
Actively Recruiting
7
Klinik und Poliklinik für Augenheilkunde - Universitätsmedizin Rostock
Rostock, Germany, 18057
Actively Recruiting
Research Team
C
Claus Cursiefen, Prof. Dr.
CONTACT
D
Deniz Hos, Dr.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here